Cognitive Decline

Understanding Cognitive Decline

Cognitive decline refers to the gradual deterioration of cognitive abilities, affecting memory, thinking, and reasoning. Recognizing early signs is crucial for timely intervention and improved quality of life.

Common Causes of Cognitive Decline

Conditions like Alzheimer’s disease, vascular dementia, and mild cognitive impairment are primary contributors to cognitive decline. Each condition presents unique challenges that require specific management approaches, especially in dementia care Nevada.

Cognitive Decline Test Online

Take control of your cognitive health with cognitive decline test online. This comprehensive, easy-to-use test helps you identify early signs of cognitive decline from the comfort of your home. Early diagnosis can lead to more effective intervention and management. Begin your path towards better brain health today.

Managing Cognitive Decline Disease

Living with cognitive decline disease in Nevada requires medication to prevent it. We offer scientifically validated intranasal nutraceuticals and develop intranasal-delivered therapeutics to treat brain neurodegenerative diseases.

Boosting Cognitive Function with Cognitive Boosters in Nevada

Explore our pioneering approach to cognitive enhancement with NeuroClimax®. It is designed for patients with cognitive decline and related conditions, our intranasal nutraceuticals offer targeted support for improving brain health and function.

The science and technology

NeuroClimax’s pre-clinical articles

– Ruben & Dagda, Raul & Mayorga, Emmanuel & Martinez, Bridget & Gallahue, Aine. (2022). Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats. International Journal of Molecular Sciences. 24. 690. 10.3390/ijms24010690
– Patented pharmaceutical technology against LewyBody dementia Parkinson’s disease US11612583B2: “Disease modifying methods for treating neurodegenerative diseases using nootropic agents” Raul Y Dagda, and Ruben K. Dagda
– National Science foundation I-corps awards to CNS Curative Technologies: Patients interviews for medical necessities for NeuroClimax development

https://www.nsf.gov/awardsearch/showAward?AWD_ID=2135052

4.- Vazquez-Mayorga E, Grigoruta M, Dagda R, Martinez B, Dagda RK. Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats. J Parkinson’s Dis. 2022;12(3):831-850. doi: 10.3233/JPD-213016. PMID34957950;

Third party studies of the ingredients

5.- PMCID: PMC9108570. Soman SK, Tingle D, Dagda RY, Torres M, Dagda M, Dagda RK. Cleaved PINK1 induces neuronal plasticity through PKA-mediated BDNF functional regulation. J Neurosci Res. 2021 Sep;99(9):2134-2155. doi: 10.1002/jnr.24854. Epub 2021 May 27. PMID: 34046942; PMCID: PMC8513622.

6.- Swain, M., Dagda, RY, Soman, S., Tapia, K., Dagda, RK.K. Brain-Derived Neurotrophic Factor protects neurons by stimulating mitochondrial function through Protein Kinase A, 2023, In-Press, Journal of Neurochemistry

7.- Seamon KB, Padgett W., Daly JW Forskolin unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. USA. 1981;78:3363–3367. doi: 10.1073/pnas.78.6.3363.

8.- Owona BA, Zug C., Schluesener HJ, Zhang ZY Protective Effects of Forskolin on Behavioral Deficits and Neuropathological Changes in a Mouse Model of Cerebral Amyloidosis. J. Neuropathol. Exp. Neurol. 2016;75:618–627. doi: 10.1093/jnen/nlw043.

9.- Sangeetha S., Samanta MK, Manjunatha N., Tiwari S. Establishment of Pharmacokinetic Parameters for the Herbal Drug Containing Forskolin. J. Pharm. Res. 2011;4:2303–2306.

10.-Costa, A., et al. Front Behav Neurosci, 2015.

11.-Costa, A., et al. Front Behav Neurosci, 2015. 9:253.

12.-Dagda, R.K., Das Banerjee, T. Rev Neurosci, 2015. 26(3):359-70.

13.-Hertz, N.T., et al. Cell, 2013. 154(4):737-47.

14.-Soman, S.K., et al. J Neurosci Res, 2021. 99(9):2134-2155.

15.-Ostrovskaya, R.U., et al. Bull Exp Biol Med, 2008. 146(3):334-7.

16.-Marcer, D., Hopkins, S.M. Age Ageing, 1977. 6(2):123-31.